The first quarter of the year is not going to go down as the most memorable for blue chip public biopharmaceutical companies. March was particularly tough on them, despite a rally in the broader markets last Thursday ahead of the Easter holiday weekend. Read More
Drug development is a risky business, not only for the companies trying to bring promising new medicines to the market, but also for investors who are hoping for significant returns when regulatory approval is achieved. Read More
